journal article·2021-12

New strategy to design fluorescent substrates of carboxypeptidases using a combination of dansylated peptides and albumin

Soyeon Yoo, Min Su Han

Dyes and Pigments· Volume 196
Publisher page

Abstract

Abstract A new strategy to design a fluorescent substrate for carboxypeptidases (CPs) was devised using dansylated sarcosine (DS) and albumin as a fluorophore and signal amplifier, respectively. The fluorescent substrate was designed by attaching an amino acid or peptide, which acts as the recognition unit for CP, to the C-terminus of DS. In the presence of the target CP, the low-fluorescence substrate is hydrolyzed to a strongly fluorescent DS by binding with albumin. As a proof concept, Dansyl-Sar-Lys-Pro (DS-KP) and Dansyl-Sar-Arg (DS-R) were developed as fluorescent substrates for the angiotensin-converting enzyme and carboxypeptidase B, respectively. The CP assay system was verified to be capable of measuring the activities of both dipeptidyl-CP and mono-CP and the inhibition efficiency of various CP inhibitors, confirming its applicability as a high-throughput screening method for numerous inhibitor candidates.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Receptor Mechanisms and Signaling · Neuropeptides and Animal Physiology · Adenosine and Purinergic Signaling

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (43)

Show source-provided references
1. Carboxyterminal protein processing in health and disease: key actors and emerging technologies10.1021/pr5005746 ↗
2. Carboxypeptidases from A to Z: implications in embryonic development and Wnt binding10.1007/PL00000819 ↗
3. Crystal structure of the human angiotensin-converting enzyme–lisinopril complex10.1038/nature01370 ↗
4. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-110.1182/blood-2010-02-267740 ↗
5. The association between circulating angiotensin-converting enzyme and cardiovascular risk in the elderly: a cross-sectional study10.1177/1470320310391326 ↗
6. The first mechanism-based inactivators for angiotensin-converting enzyme10.1021/jm00100a024 ↗
7. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino) propyl] hydroxyphosphinoyl] methyl] heptanoic acid], a specific inhibitor of plasma carboxypeptidase B10.1124/jpet.103.062729 ↗
8. Design and characterization of a selenium-containing inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa), a zinc-containing metalloprotease10.1021/jm300735t ↗
9. Design, synthesis and evaluation of novel 2-butyl-4-chloroimidazole derived peptidomimetics as Angiotensin Converting Enzyme (ACE) inhibitors10.1016/j.bmc.2015.04.024 ↗
10. Preferential detection of pro‐carboxypeptidase R by enzyme‐linked immunosorbent assay10.1111/j.1348-0421.2003.tb03398.x ↗
11. A novel aggregation-induced emission based fluorescent probe for an angiotensin converting enzyme (ACE) assay and inhibitor screening10.1039/C4CC07161A ↗
12. Determination of carboxypeptidase activity in clinical pathogens by gas chromatography–mass spectrometry10.1080/00032719.2015.1092153 ↗
13. Fluorogenic probes for disease-relevant enzymes10.1039/C7CS00907K ↗
14. 1, 8-Naphthalimide based fluorescent sensors for enzymes10.1016/j.ccr.2020.213713 ↗
15. Sensors for in situ real-time fluorescence imaging of enzymes10.1016/j.chempr.2020.10.010 ↗
16. Enzyme activity–it's all about image10.1016/j.tcb.2003.11.002 ↗
17. Emerging challenges in the design of selective substrates, inhibitors and activity‐based probes for indistinguishable proteases10.1111/febs.14001 ↗
18. A rapid, simple and sensitive fluorescence method for the assay of angiotensin-I converting enzyme10.1016/j.foodchem.2005.06.006 ↗
19. A continuous fluorescence resonance energy transfer angiotensin I-converting enzyme assay10.1038/nprot.2006.306 ↗
20. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis10.1053/jhep.2003.50277 ↗
21. Potential antioxidant and angiotensin I-converting enzyme inhibitory activity in crust of dry-aged beef10.1038/s41598-020-64861-0 ↗
22. Improved method for direct high-performance liquid chromatography assay of angiotensin-converting enzyme-catalyzed reactions10.1016/S0021-9673(02)00052-3 ↗
23. Miniaturizable homogenous time-resolved fluorescence assay for carboxypeptidase B activity10.1016/S0003-2697(03)00048-4 ↗
24. Establishment of molecular design strategy to obtain activatable fluorescent probes for carboxypeptidases10.1021/jacs.7b11014 ↗
25. Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin10.1016/j.jsb.2010.10.004 ↗
26. A fluorescent probe for butyrylcholinesterase activity in human serum based on a fluorophore with specific binding affinity for human serum albumin10.1039/C9CC07737E ↗
27. ACE inhibitors—a cornerstone of the treatment of heart failure10.1056/NEJM199108013250508 ↗
28. Why not prescribe the best drugs for hypertension now?10.1038/sj.jhh.1001576 ↗
29. Structural basis for inhibition of carboxypeptidase B by selenium-containing inhibitor: selenium coordinates to zinc in enzyme10.1021/jm400816v ↗
30. Novel small molecule inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) from natural product anabaenopeptin10.1021/jm501840b ↗
31. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor10.1074/jbc.270.24.14477 ↗
32. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B: modulation by glycosaminoglycans10.1074/jbc.274.49.35046 ↗
33. Peptidase specificity characterization of C-and N-terminal catalytic sites of angiotensin I-converting enzyme10.1021/bi9928905 ↗
34. Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate10.1016/j.ab.2005.01.039 ↗
35. A continuous fluorescent assay for the determination of plasma and tissue angiotensin I-converting enzyme activity10.1590/S0100-879X2005000600007 ↗
36. Isolation and characterization of angiotensin converting enzyme from human kidney10.1093/oxfordjournals.jbchem.a133596 ↗
37. An intramolecularly quenched fluorescent tripeptide as a fluorogenic substrate of angiotensin‐i‐converting enzyme and of bacterial dipeptidyl carboxypeptidase10.1111/j.1432-1033.1978.tb12375.x ↗
38. Ostrich (Struthio camelus) carboxypeptidase B: purification, kinetic properties and characterization of the pancreatic enzyme10.1016/1357-2725(95)00166-2 ↗
39. Focus on increased serum angiotensin-converting enzyme level: from granulomatous diseases to genetic mutations10.1016/j.clinbiochem.2018.06.010 ↗
40. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties10.1074/jbc.273.4.2127 ↗
41. Characteristics of carboxypeptidase B from pyloric ceca of the starfish Asterina pectinifera10.1016/j.foodchem.2005.01.001 ↗
42. A simpler sampling interface of venturi easy ambient sonic-spray ionization mass spectrometry for high-throughput screening enzyme inhibitors10.1016/j.aca.2016.01.051 ↗
43. The potential role of serum angiotensin-converting enzyme in coronavirus disease 201910.1186/s12879-020-05619-x ↗